Key Developments: Ellex Medical Lasers Ltd (ELX.AX)

ELX.AX on Australia Stock Exchange

0.34AUD
9 Jul 2014
Price Change (% chg)

$-0.01 (-4.29%)
Prev Close
$0.35
Open
$0.35
Day's High
$0.36
Day's Low
$0.34
Volume
66,168
Avg. Vol
32,866
52-wk High
$0.47
52-wk Low
$0.21

Search Stocks

Latest Key Developments (Source: Significant Developments)

Ellex Medical Lasers Ltd announces further positive data for 2RT treatment of early AMD
Wednesday, 21 May 2014 09:00am EDT 

Ellex Medical Lasers Ltd:Announces data from a 24-month follow up of the pilot study investigating the efficacy of the company's Retinal Rejuvenation Therapy (2RT) in the treatment of early AMD.The data was presented in summary form by Dr. Erica L. Fletcher of the University of Melbourne, at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting in Orlando, FL and is currently being considered for publication in a peer-reviewed journal.The study showed that nanosecond laser treatment reduced drusen area in 35-40 pct of treated eyes after 12 and 24 months, compared with reduced drusen area in 5-11 pct of eyes in the natural history cohort.  Full Article

Ellex Medical Lasers Ltd gives H1 2013 guidance
Wednesday, 29 Jan 2014 08:30pm EST 

Ellex Medical Lasers Ltd:Sees H1 2013 profit before tax of about $650,000.Sees H1 2013 revenue to be $25.9 million.Says the increase in revenues is primarily attributable to the sales increase in the USA following the introduction of Ellex’s SLT Laser range into the US market in July 2013.  Full Article

Ellex Medical Lasers Ltd completes acquisition of canaloplasty business of iScience Interventional Inc
Sunday, 5 Jan 2014 06:23pm EST 

Ellex Medical Lasers Ltd:Says that, pursuant to the binding agreement it entered into on Dec. 18, 2013, it has acquired the canaloplasty business of US-based iScience Interventional, Inc., which comprises iTRACK 250 catheter and suture device.Says on Dec. 31, 2013 (California time) Ellex paid $1.5 mln in exchange for iScience Interventional's canaloplasty business, including accounts receivable (about $0.5 mln) and inventory (about $0.5 mln).Says it also covers manufacturing machinery and equipment and intellectual property.Says consideration for the purchase also includes an earn-out over several years based on a percentage of business revenues.Says Ellex has retained six permanent staff plus a small transition team, who will all commence with for Ellex on Jan. 6.Says the business will continue to operate from Menlo Park, California.  Full Article

Ellex Medical Lasers Ltd announces acquisition of north american glaucoma treatment consumable device business and completion of A$3 mln capital raise
Thursday, 19 Dec 2013 05:52pm EST 

Ellex Medical Lasers Ltd:Says has entered into agreement to acquire North American glaucoma consumable device business.Says for commercial reasons, the name if the company cannot be identified until after settlement of transaction expected to occur on Dec. 31.Says gross proceeds of A$3 mln under the placement will fund the upfront $1.6 mln consideration of the acquisition while remaining funds will be applied to working capital.Says the placement of 10 mln shares was completed at an issue price of A$0.30 per share raising A$3 mln and represents a 6.25 pct discount to the closing price of the company's shares on the ASX on Dec 17.Says it expects that placement share will be issued on Dec. 30.  Full Article

Ellex Medical Lasers Ltd Announces Release of Positive Pilot Study Results for 2RT Treatment of Early AMD
Sunday, 13 Oct 2013 06:50pm EDT 

Ellex Medical Lasers Ltd announced that the results of a pilot study to investigate the efficacy of the Company’s Retinal Rejuvenation Therapy (2RT) in the treatment of early Age-Related Macular Degeneration (AMD) have been released and published in the peer-reviewed, scientific publication Clinical & Experimental Ophthalmology. 50 patients with bilateral at risk intermediate AMD were enrolled in the study with a 12-month followup period. Drusen are the accumulation of waste deposits in the macula and are a key risk factor to progression to end-stage, blinding AMD. These drusen were reduced in 44% of treated eyes. Of the 11 patients at greatest risk of disease progression (flicker defect >15dB), seven improved sufficiently to be taken out of this high-risk category. According to Tom Spurling, the publication of the results is a major milestone in the Company’s clinical investigations: “The study concluded that the application of 2RT produced improvements in macula function and appearance amongst the patient cohort and that as such it warrants ongoing evaluation as an early intervention for AMD.” Until now, treatment options have been restricted to targeting late-stage complications associated with the wet form of AMD, which only accounts for 10-15% of all people who suffer from AMD.  Full Article

Ellex Medical Lasers Ltd Announces Ownership Interest Of National Nominees Ltd
Thursday, 3 Oct 2013 12:00am EDT 

Ellex Medical Lasers Ltd announced that National Nominees Ltd as Custodian for Australian Ethical Investment holds 8,794,563 person's votes representing 9.01%.  Full Article

Ellex Medical Lasers Ltd Completes Placement To Raise $3.3 Million
Wednesday, 18 Sep 2013 07:13pm EDT 

Ellex Medical Lasers Ltd announced that it has completed a placement to institutional and sophisticated investors, raising gross proceeds of approximately AUD3.3 million (Placement). The Placement of approximately 12.7 million ordinary shares was completed at an issue price of AUD0.26 per share, a 13.3% discount to the closing price of the Company’s shares on the ASX on September 16, 2013. Taylor Collison Limited was the Lead Manager for the Placement, which was oversubscribed. It is expected that the Placement shares will be issued on September 26, 2013.  Full Article

Ellex Medical Lasers Ltd Secures US FDA Approval for 2RT in Treatment of Diabetic Eye Disease
Wednesday, 17 Jul 2013 07:42pm EDT 

Ellex Medical Lasers Ltd announced that it has secured US FDA 510(k) approval for its Retinal Rejuvenation Therapy (2RT) in the treatment of Clinically Significant Macular Edema (CSME), the most common form of diabetic eye disease which can result in legal blindness. This follows the Company's announcement in 2012 that it had received a CE Mark (European Conformity) for 2RT for the same indication. Whilst treatment options already exist for CSME, including the Company’s Integre photocoagulation laser portfolio, 2RT achieves similar clinical outcomes without the collateral damage to the retina associated with conventional thermal photocoagulation.  Full Article

Ellex Medical Lasers Ltd Announces H1 2012/2013 Guidance
Wednesday, 30 Jan 2013 01:25am EST 

Ellex Medical Lasers Ltd announced that it expects profit before tax to be between AUD 50,000 and AUD 100,000 for the six months ended December 31, 2012. This compares to a profit before tax of AUD 949,246 for the six months ended December 31, 2011. Despite a 4% improvement in group revenues compared to the period ended June 30, 2012, revenues are expected to be 16% lower than the prior comparable period.  Full Article

Ellex Medical Lasers Ltd Secures Contract From Signostics Limited
Thursday, 1 Nov 2012 04:45am EDT 

Ellex Medical Lasers Ltd announced that it has been awarded a contract by Signostics Limited to manufacture the sub-assembly of the Signostics ultrasound device, Signos RT.  Full Article

Search Stocks